Product/Composition:- | Tenofovir DF + Emtricitabine + Rilpivirine |
---|---|
Strength:- | TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg |
Form:- | Tablet |
Reference Brands:- | Complera(US); Eviplera(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Tenofovir DF + Emtricitabine + Rilpivirine, sold as Complera (US) and Eviplera (EU), is a once-daily HIV-1 treatment combining three antiretrovirals in one tablet. It’s FDA and EMA approved and must be taken with food.
Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Rilpivirine is a once-daily, fixed-dose combination used for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. Marketed under the brand names Complera (US) and Eviplera (EU), it combines three powerful antiretroviral agents: TDF (a nucleotide reverse transcriptase inhibitor), Emtricitabine (an NRTI), and Rilpivirine (a non-nucleoside reverse transcriptase inhibitor). This single-tablet regimen simplifies HIV treatment, enhances patient adherence, and effectively suppresses viral load. Approved by the FDA and EMA, it is recommended for patients without resistance to any of its components and should be taken with a meal for optimal absorption.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications